Structure Therapeutics In... (GPCR)
NASDAQ: GPCR
· Real-Time Price · USD
19.00
0.18 (0.96%)
At close: Aug 27, 2025, 3:59 PM
19.00
0.00%
After-hours: Aug 27, 2025, 04:34 PM EDT
Structure Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 |
Revenue | 1.78M | 1.78M | 1.78M | 1.33M | 1.33M | 1.33M | 1.33M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 1.81M | 1.19M | 1.16M | 1.44M | 1.52M | 1.45M | 945.9K | 812.74K | 461.72K | 455.68K | 454.19K | 437.69K | 437.69K | 283.46K | 131.25K |
Gross Profit | -917.48K | -295.22K | -267.18K | -108.79K | -192.64K | -121.16K | 384.06K | -812.74K | -461.72K | -455.68K | -454.19K | -437.69K | -437.69K | -283.46K | -131.25K |
Operating Income | -219.91M | -182.52M | -158.23M | -142.16M | -122.47M | -115.14M | -102.78M | -84.74M | -71.28M | -59.26M | -52.56M | -39.62M | -26.93M | -12.97M | -13.27K |
Interest Income | 41.28M | 39.65M | 36.05M | 31.6M | 22.23M | 17.7M | 13.4M | 8.08M | 5.39M | 2.6M | 899.51K | 1.91 | 1.91 | 1.91 | 1.91 |
Pretax Income | -178.7M | -142.94M | -122.22M | -110.69M | -100.26M | -97.44M | -89.38M | -76.62M | -65.51M | -56.23M | -51.3M | -39.26M | -26.92M | -13.03M | -13.28K |
Net Income | -179.17M | -143.32M | -122.53M | -110.55M | -100.44M | -97.68M | -89.62M | -76.99M | -67.06M | -57.73M | -52.84M | -40.98M | -27.04M | -13.1M | -15.43K |
Selling & General & Admin | 55.2M | 51.52M | 49.41M | 46.59M | 41.98M | 37.29M | 32.47M | 26.32M | 21.22M | 18.42M | 16.37M | 11.78M | 8.24M | 4.46M | 3.37K |
Research & Development | 163.85M | 131M | 108.81M | 95.51M | 80.42M | 77.78M | 70.24M | 58.42M | 50.07M | 40.84M | 36.19M | 27.84M | 18.68M | 8.5M | 9.91K |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 219.05M | 182.52M | 158.23M | 142.09M | 122.4M | 115.07M | 102.71M | 84.74M | 71.28M | 59.26M | 52.56M | 39.62M | 26.93M | 12.97M | 13.27K |
Interest Expense | n/a | n/a | 6.01M | 6.01M | 6.01M | 8.83M | 2.83M | 2.83M | 2.83M | n/a | 69K | 70K | 70K | 70K | 1K |
Selling & Marketing Expenses | n/a | n/a | n/a | -205.62K | -205.62K | -205.62K | -205.62K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 219.91M | 182.52M | 158.23M | 142.16M | 122.47M | 115.14M | 102.78M | 84.74M | 71.28M | 59.26M | 52.56M | 39.62M | 26.93M | 12.97M | 13.27K |
Income Tax Expense | 465.49K | 379K | 310K | -138K | 175K | 240K | 236K | 368K | 36K | -18K | 17K | 197.08K | 124.08K | 60.08K | 81.00 |
Shares Outstanding (Basic) | 19.18M | 57.35M | 57.29M | 57.21M | 49.41M | 46.57M | 46.41M | 38.32M | 38.25M | 37.42M | 36.59M | 39.12M | 36.59M | 36.59M | 36.59M |
Shares Outstanding (Diluted) | 19.18M | 57.35M | 57.29M | 57.21M | 49.41M | 46.57M | 46.41M | 38.32M | 38.25M | 37.42M | 36.59M | 39.12M | 36.59M | 36.59M | 36.59M |
EPS (Basic) | -5.28 | -2.58 | -2.34 | -2.25 | -2.28 | -2.34 | -2.25 | -2.04 | -2.67 | -2.49 | -2.37 | -2.46 | -1.2 | -0.78 | -0.42 |
EPS (Diluted) | -5.28 | -2.58 | -2.34 | -2.25 | -2.28 | -2.34 | -2.25 | -2.04 | -2.67 | -2.49 | -2.37 | -2.46 | -1.2 | -0.78 | -0.42 |
EBITDA | -209.28M | -181.48M | -157.24M | -141.35M | -121.93M | -114.76M | -102.54M | -84.52M | -70.99M | -58.98M | -52.28M | -52.57M | -39.95M | -26.05M | -13.17M |
EBIT | -210.95M | -182.52M | -158.23M | -142.16M | -122.47M | -115.14M | -102.78M | -84.74M | -71.28M | -59.26M | -52.56M | -52.88M | -40.19M | -26.23M | -13.27M |
Depreciation & Amortization | 1.67M | 1.04M | 992K | 808K | 622K | 550.26K | 481.96K | 540.72K | 537.72K | 531.68K | 530.19K | 513.69K | 437.69K | 283.46K | 131.25K |